scholarly journals A Randomized, Evaluator-Blinded, Split-Face Comparison Study of the Efficacy and Safety of a Novel Mannitol Containing Monophasic Hyaluronic Acid Dermal Filler for the Treatment of Moderate to Severe Nasolabial Folds

2016 ◽  
Vol 28 (3) ◽  
pp. 297 ◽  
Author(s):  
Byung Wook Kim ◽  
Ik Jun Moon ◽  
Woo Jin Yun ◽  
Bo Young Chung ◽  
Sang Duck Kim ◽  
...  
2013 ◽  
Vol 25 (5) ◽  
pp. 448-452 ◽  
Author(s):  
Do Young Rhee ◽  
Chong Hyun Won ◽  
Sung Eun Chang ◽  
Tai Kyung Noh ◽  
Myoung Shin Kim ◽  
...  

2017 ◽  
Vol 17 (4) ◽  
pp. 584-589
Author(s):  
Hyun Jung Kwon ◽  
Eun Jung Ko ◽  
Sun Young Choi ◽  
Eun Ja Choi ◽  
Yu-Jin Jang ◽  
...  

2015 ◽  
Vol 2015 ◽  
pp. 1-7 ◽  
Author(s):  
Daisy Kopera ◽  
Michael Palatin ◽  
Rolf Bartsch ◽  
Katrin Bartsch ◽  
Maria O’Rourke ◽  
...  

The dermal filler Princess VOLUME is a highly cross-linked, viscoelastic hyaluronic acid injectable gel implant used for aesthetic treatment. To evaluate the efficacy and safety of Princess VOLUME in the treatment of nasolabial folds, an open-label uncontrolled, multicenter study was conducted. Forty-eight subjects were recruited who had moderate to deep wrinkles, according to the Modified Fitzpatrick Wrinkle Scale (MFWS). Subjects received Princess VOLUME in both nasolabial folds at Day 0. Nasolabial fold severity was evaluated at 30, 90, 180, and 270 days after treatment, using the MFWS and the Global Aesthetic Improvement Scale (GAIS). Adverse events and treatment site reactions were recorded. Among the 48 subjects, 93.8% were female with a median age of 52 years. There were significant improvements(P<0.0001)in the MFWS scores at 30, 180, and 270 days after treatment compared with those at baseline, with a mean decrease of 1.484 (±0.408), 1.309 (±0.373), and 1.223 (±0.401), respectively; hence the primary endpoint was achieved and clinical efficacy demonstrated. Princess VOLUME was well tolerated, and most adverse events were injection site reactions of mild to moderate severity. Subject satisfaction (97.9%), subject recommendation of the treatment (93.6%), and investigators GAIS scores (97.9% improvement) were high.


2012 ◽  
Vol 38 (7pt2) ◽  
pp. 1143-1150 ◽  
Author(s):  
Welf Prager ◽  
Esther Wissmueller ◽  
Isabel Havermann ◽  
Eva K. Bee ◽  
David J. Howell ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document